Candel Therapeutics publishes phase 2a NSCLC trial data in peer-reviewed journal

October 1, 2026 8:05 AM

Candel Therapeutics, Inc. (Nasdaq: CADL) announced the publication of final phase 2a clinical trial results for aglatimagene besadenovec plus valacyclovir ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found